Royal Bank Of Canada Has Lowered Expectations for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Key Points

• Royal Bank of Canada trimmed its price target for Alnylam from $450 to $445 but kept an "outperform" rating, implying roughly a 48% upside from recent share levels.
• Q1 results beat expectations — EPS $1.99 vs. ~$0.90 expected and revenue $1.17B (up ~96% YoY) — yet the stock traded down to about $300, while analysts' consensus is a "Moderate Buy" with an average price target near $472.
• An outside review warned ALNY shares carry a "high risk of significant losses," and insiders have sold about 38,656 shares in the past 90 days (insiders own ~0.86% while institutions own ~92.97%).

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) had its target price reduced by research analysts at Royal Bank Of Canada from $450.00 to $445.00 in a report released on Friday,Benzinga reports. The firm presently has an "outperform" rating on the biopharmaceutical company's stock. Royal Bank Of Canada's target price suggests a potential upside of 48.16% from the company's current price.

Several other research analysts have also recently weighed in on the company. Raymond James Financial restated an "outperform" rating and issued a $472.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, January 12th. Jefferies Financial Group restated a "hold" rating and issued a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. Freedom Capital upgraded Alnylam Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, February 17th. Bank of America restated a "buy" rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. Finally, Morgan Stanley decreased their price target on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an "equal weight" rating for the company in a research note on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $471.96.

Alnylam Pharmaceuticals Stock Down 3.0%

NASDAQ:ALNY traded down $9.14 during trading hours on Friday, reaching $300.36. 321,239 shares of the company traded hands, compared to its average volume of 1,308,125. The business's 50-day moving average price is $320.11 and its two-hundred day moving average price is $377.45. The stock has a market capitalization of $40.08 billion, a P/E ratio of 175.95 and a beta of 0.39. Alnylam Pharmaceuticals has a 1 year low of $245.96 and a 1 year high of $495.55. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.90 by $1.09. The business had revenue of $1.17 billion during the quarter, compared to analysts' expectations of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The firm's quarterly revenue was up 96.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.44) earnings per share. Analysts predict that Alnylam Pharmaceuticals will post 6.75 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Jeffrey V. Poulton sold 2,206 shares of the company's stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $722,795.90. Following the completion of the sale, the executive vice president owned 64,273 shares in the company, valued at approximately $21,059,048.45. This represents a 3.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Tolga Tanguler sold 1,598 shares of the company's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total value of $523,584.70. Following the sale, the executive vice president owned 36,606 shares of the company's stock, valued at approximately $11,993,955.90. This trade represents a 4.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 38,656 shares of company stock valued at $12,370,696 in the last 90 days. 0.86% of the stock is owned by company insiders.

Institutional Trading of Alnylam Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Brighton Jones LLC bought a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at about $243,000. Geneos Wealth Management Inc. grew its holdings in Alnylam Pharmaceuticals by 372.3% during the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company's stock valued at $60,000 after purchasing an additional 175 shares during the period. Flow Traders U.S. LLC bought a new stake in Alnylam Pharmaceuticals during the second quarter valued at about $241,000. Daiwa Securities Group Inc. grew its holdings in Alnylam Pharmaceuticals by 0.3% during the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company's stock valued at $4,220,000 after purchasing an additional 35 shares during the period. Finally, NewEdge Advisors LLC grew its holdings in Alnylam Pharmaceuticals by 70,300.0% during the second quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company's stock valued at $229,000 after purchasing an additional 703 shares during the period. Hedge funds and other institutional investors own 92.97% of the company's stock.

Key Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q1 results significantly beat expectations: EPS $1.99 vs. consensus ~$0.90–1.43 and revenue $1.17B (up ~96% YoY), showing strong topline growth and margin improvement. Earnings Release
• Positive Sentiment: Multiple brokerages reiterate buy/positive views (consensus called a "Moderate Buy"); H.C. Wainwright remains a Buy, supporting analyst confidence in the franchise. Brokerage Consensus H.C. Wainwright
• Positive Sentiment: Wells Fargo nudged its price target slightly higher (to $377) while keeping an "equal weight" rating — a modest vote of confidence but not an outright upgrade. Wells Fargo PT Note
• Neutral Sentiment: FY‑2026 revenue guidance was set to a $5.3B–$5.8B range (consensus ~ $5.6B). The range includes the street number but its breadth may introduce caution around execution. Company Press Release / Slide Deck
• Neutral Sentiment: Detailed Q1 commentary and management remarks are available in the earnings call transcript and analyst write‑ups — useful for assessing product uptake and 2026 drivers but not news by themselves. Earnings Call Transcript Zacks Analysis
• Negative Sentiment: An outside review flagged that ALNY shares carry a "high risk of significant losses" under a Regulation category disclosure — a headline that can drive near‑term selling and increase perceived regulatory/operational risk. Outside Review Warning

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.